Literature DB >> 34480606

The synergistic role of TNFA - 308G/A and IL10 - 1082A/G polymorphisms in ankylosing spondylitis.

Mariana Ivanova1, Irena Manolova2, Rumen Stoilov3, Spaska Stanilova2.   

Abstract

OBJECTIVE: Genetic polymorphisms of the cytokine genes could alter their protein expression, thus creating a genetic basis of dysregulated cytokine production and function, which render them as excellent candidates predisposing to autoimmune diseases. We investigated single nucleotide polymorphisms (SNPs) at TNFA - 308G/A and IL10 - 1082A/G locus to identify their involvement, separately or in combination, in determining susceptibility to ankylosing spondylitis (AS), as well as their functional connections with relevant serum cytokines and associations with disease characteristics.
METHODS: Eighty-one AS patients and 215 healthy controls were genotyped by polymerase chain reaction-based method; 76 patients and sex-matched controls were also subjected to analysis of serum TNF-α and IL-10 levels by enzyme-linked immunosorbent assay.
RESULTS: We identified the homozygous genotype GG of the TNFA-308 significantly more common in patients than controls; whereas the - 308 minor A-allele predicts a threefold decreased risk against developing AS and shows associations with milder radiographic spinal impairments and functional limitations. This protective effect was multiplied by fivefold in synergistic interaction with the homozygous - 1082AA genotype of the IL10 which acts as a modifying factor, since IL10 - 1082A/G SNPs by itself did not have a significant impact on AS genetic susceptibility. In comparison with controls, AS patients had significantly elevated mean serum TNF-α levels and decreased mean IL-10 concentrations not restricted to any particular genotype.
CONCLUSION: TNFA - 308 A-allele is essential for reducing susceptibility to AS, with a considerable synergistic protective effect of the combined TNF-α - 308 (GA/AA)/IL-10 - 1082AA genotypes. In addition, the presence of this variant allele is associated with more benign clinical phenotype of the disease. No conclusive statements on the functional relevance of both gene variants on cytokines production should be made.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  AS; Cytokine gene polymorphisms; Disease outcomes; IL-10; SNP; TNF-α

Mesh:

Substances:

Year:  2021        PMID: 34480606     DOI: 10.1007/s00296-021-04984-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  Evaluation of the T helper 17 axis in ankylosing spondylitis.

Authors:  Ali Taylan; Ismail Sari; Didem L Kozaci; Arif Yuksel; Safak Bilge; Yasar Yildiz; Gulten Sop; Isil Coker; Necati Gunay; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2011-07-16       Impact factor: 2.631

Review 2.  The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment.

Authors:  H Jethwa; P Bowness
Journal:  Clin Exp Immunol       Date:  2015-09-30       Impact factor: 4.330

Review 3.  Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.

Authors:  John C Davis
Journal:  Semin Arthritis Rheum       Date:  2005-02       Impact factor: 5.532

4.  Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

Authors:  J Braun; M Bollow; L Neure; E Seipelt; F Seyrekbasan; H Herbst; U Eggens; A Distler; J Sieper
Journal:  Arthritis Rheum       Date:  1995-04

Review 5.  Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease.

Authors:  Maqsood M Elahi; Kamlesh Asotra; Bashir M Matata; Sarabjit S Mastana
Journal:  Biochim Biophys Acta       Date:  2009-03

6.  Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity.

Authors:  J Gratacós; A Collado; X Filella; R Sanmartí; J Cañete; J Llena; R Molina; A Ballesta; J Muñoz-Gómez
Journal:  Br J Rheumatol       Date:  1994-10

Review 7.  Ankylosing spondylitis.

Authors:  Jürgen Braun; Joachim Sieper
Journal:  Lancet       Date:  2007-04-21       Impact factor: 79.321

8.  Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization.

Authors:  G E Nedwin; S L Naylor; A Y Sakaguchi; D Smith; J Jarrett-Nedwin; D Pennica; D V Goeddel; P W Gray
Journal:  Nucleic Acids Res       Date:  1985-09-11       Impact factor: 16.971

9.  Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis.

Authors:  Xinwei Wang; Zhiming Lin; Qiujing Wei; Yingjuan Jiang; Jieruo Gu
Journal:  Rheumatol Int       Date:  2009-02-27       Impact factor: 2.631

Review 10.  The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science.

Authors:  Abdulla Watad; Charlie Bridgewood; Tobias Russell; Helena Marzo-Ortega; Richard Cuthbert; Dennis McGonagle
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.